true
- Overview
- Resources
A bloodstream infection (BSI) can lead to a dysregulated immune response if untreated. BSI’s can lead to potentially life-threatening conditions, including sepsis.
Blood culture is a critical tool in the diagnosis and management of sepsis.
Identifying BSIs and treating symptoms quickly and effectively may impact sepsis-related mortality.2,3,4
To make substantial improvements to BSI testing, consider the entire diagnostic pathway – from blood culture collection to result.
Learn more in the Bloodstream Infection (BSI) Infographic
Did you know?
- Inconsistent blood culture collection can lead to contaminated blood culture bottles that inadvertently flag positive.5,6,7
- Inconsistent collection practices can also lead to under-filled bottles that prompt a redraw.5,6
- Under-filled bottles can result in under-diagnosis of BSI’s and potentially longer time to detection.5,6
- Contaminated blood cultures could mean that a patient remains on inappropriate antibiotic treatment for longer than necessary.5,7
Have you realized?
The ability to appropriately treat bloodstream infections (BSIs) and sepsis relies largely on the quality of your sample, and on the speed and accuracy of your lab’s identification (ID) and antimicrobial susceptibility testing (AST) systems. Challenges related to limited organism coverage, outdated breakpoints, and inefficient workflows may further disrupt patient care and can lead to delayed results, added tests, and higher costs.
It's time for a more holistic approach for the management of BSI testing. The BD ID/AST offering, as part of the complete BD BSI solution, helps enable clinicians to make critical patient management decisions based on the speed, accuracy, and breadth of coverage of the BD portfolio.
Related Solutions
Sepsis Management
- Rudd, et al. Lancet 2020; 395:200-11.
- Kumar A., et al. Critical Care Medicine 2006; 34(6):1589-1596.
- Roimi M., et al. (2020). Intensive Care Medicine 2020; 46: 454–462.
- Adrie C., et al. Journal of Infection 2017; 74: 131-141.
- Lamy B., et al. Frontiers in Microbiology, 7 (2016), article 697.
- Banerjee R., et al. CID 2016; 63(10): 1332-9.
- Hall K., et al. Clinical Microbiology Reviews 2006; 19(4):788-802
* MALDI Biotyper CA System can only be sold in the USA and Puerto Rico.
The MALDI Biotyper is also available in Research Use Only (RUO), General Purpose (GP) and IVD CE labels. Please contact your local representative for availability in your country.
-
Advanced fluorescence detection technology, exceptional media performance and instrument reliability—adding vial-activated workflow, advanced ergonomics, blood culture observation and customer-focused data management.
-
Time to detection is important during the analytical phase. Learn about a full spectrum of blood culture media solutions.
-
The BD Phoenix™ M50 instrument provides clinicians with accurate and timely identification and susceptibility results to help guide their therapy and patient management decisions.
-
BD Phoenix™ panels provide accurate, rapid identification and susceptibility results for most clinically significant aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria, as well as identification of yeast and yeast-like organisms.
-
BD Synapsys™ solution enables laboratories to address challenges and improve laboratory outcomes. It enables labs to maximize performance using enhanced microbiology diagnostic informatics through a single, advanced platform with an intuitive, personalized user interface.
-
The BD™ Bruker MALDI Biotyper® CA System identifies microorganisms using MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight) mass spectrometry.
-
With proprietary BD PentaPoint™ and BD RightGauge™ needle technology, the BD Vacutainer® UltraTouch™ push button blood collection set aims to improve the patient experience by enhancing comfort, enabling clinicians to better access difficult veins, and reducing overall procedure times.
* By clicking this link you are leaving bd.com and going to a third party website
true
